# An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

> **NCT04922021** · PHASE2 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 58 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** LEO 138559
- **DRUG:** LEO 138559 placebo

## Key facts

- **NCT ID:** NCT04922021
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-14
- **Primary completion:** 2022-06-02
- **Final completion:** 2022-09-26
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2025-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04922021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04922021, "An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04922021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*